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Type VI CRISPR-Cas systems contain programma-
ble single-effector RNA-guided RNases, including
Cas13b, one of the four known family members.
Cas13b, which has been used for both RNA editing
and nucleic acid detection, is unique among type VI
CRISPR effectors in its linear domain architecture
and CRISPR RNA (crRNA) structure. Here, we report
the crystal structure of Prevotella buccae Cas13b
(PbuCas13b) bound to crRNA at 1.65 A˚ resolution.
This structure, combined with biochemical experi-
ments assaying the stability, kinetics, and function
of Cas13b, provides a mechanistic model for
Cas13b target RNA recognition and identifies fea-
tures responsible for target and cleavage specificity.
Based on these observations, we generated Cas13b
variants with altered cleavage preferences, which
may expand the utility of nuclease-basedRNAdetec-
tion assays and other applications of Cas13b in
mammalian cells.INTRODUCTION
A number of new Cas enzymes and CRISPR systems with
novel properties have been discovered recently. Notable
among these new discoveries are the class 2 type VI
CRISPR-Cas13 systems, which use a single enzyme to target
RNA using a programmable CRISPR RNA (crRNA) guide (Abu-
dayyeh et al., 2016; Konermann et al., 2018; Shmakov et al.,
2015, 2017; Smargon et al., 2017; Yan et al., 2018). Cas13Cell R
This is an open access article undbinding to target single-stranded RNA activates a general
RNase activity that cleaves the target and degrades surround-
ing RNA non-specifically, known as collateral activity or trans-
cleavage (Abudayyeh et al., 2016; East-Seletsky et al., 2016).
Type VI systems have been used for RNA knockdown, tran-
script labeling, splicing modulation, and ultra-sensitive virus
detection (Abudayyeh et al., 2016, 2017; East-Seletsky et al.,
2016, 2017; Gootenberg et al., 2017, 2018; Konermann et al.,
2018; Smargon et al., 2017; Yan et al., 2018). In addition,
nuclease dead Cas13 forms the basis for the RNA editing plat-
form REPAIR (RNA Editing for Precise A-to-I Replacement),
which relies on the targeting activity of Cas13 and the adeno-
sine deaminase activity of ADAR to achieve precise base edit-
ing (Cox et al., 2017).
CRISPR-Cas13 systems are further divided into four sub-
types based on the identity of the Cas13 protein (Cas13a–d)
(Shmakov et al., 2017). All Cas13 protein family members
contain two Higher Eukaryotes and Prokaryotes Nucleotide-
binding (HEPN) domains. Unlike Cas13a, Cas13c, and
Cas13d, however, in Cas13b the HEPN domains are at the
extreme N and C termini of the linear protein, suggesting it
may adopt a unique three-dimensional conformation (Shmakov
et al., 2017; Smargon et al., 2017). Additionally, the direct
repeat of the Cas13b crRNA is at the 30 end, which is the oppo-
site orientation found in other type VI systems (Abudayyeh
et al., 2016; Cox et al., 2017; Konermann et al., 2018; Smargon
et al., 2017; Yan et al., 2018). Here we report the structure of
Prevotella buccae Cas13b (PbuCas13b) in complex with a
crRNA handle and partial spacer at 1.65 A˚ resolution. This
structural information together with biochemical characteriza-
tion of RNA targeting provide a model for target recognition
and specificity by Cas13b that is distinct from other known pro-
grammable nucleic acid targeting systems.eports 26, 3741–3751, March 26, 2019 ª 2019 The Author(s). 3741
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. The Crystal Structure of the
PbuCas13b-crRNA Binary Complex
(A) Linear domain organization of PbuCas13b.
Active site positioning is denoted by asterisks.
(B) The overall structure of PbuCas13b. Two views
are rotated 180 degrees from each other. Domains
are colored consistent with the linear domain map,
and the crRNA is colored red. HEL1, Helical-1;
HEL2, Helical-2; HEP1, HEPN1; HEP2, HEPN2; N,
N terminus; C, C terminus.
(C) Space-filling model of PbuCas13b, each view
rotated 180 degrees from each other.RESULTS
High-Resolution Crystal Structure of PbuCas13b
To understand the architecture of Cas13b, we solved a crystal
structure of PbuCas13b complexed with a 36-nt direct repeat
sequence and a 5-nt spacer at 1.65 A˚ (Figure 1; Table 1). The do-
mains and organization are unique among other known struc-
tures; however, the overall shape of PbuCas13b is bilobed,
similar to other class 2CRISPR effectors (Jinek et al., 2014; Knott
et al., 2017; Liu et al., 2017a, 2017b; Nishimasu et al., 2014; Ya-
mano et al., 2016; Yang et al., 2016). Five domains are apparent
within the structure: two HEPN domains (HEPN1 and HEPN2),
two predominantly Helical domains (Helical-1 and Helical-2),
and a domain that caps the 30 end of the crRNA with two beta
hairpins (Lid domain) (Figure 1). The bound crRNA is coordinated
within the Helical-1, Helical-2, and Lid domains, and the spacer
protrudes into a large, positively charged central channel running3742 Cell Reports 26, 3741–3751, March 26, 2019through the center of the molecule, pro-
tected from the solvent (Figures S1A–
S1D).
TheDomain Architecture of Cas13b
Both HEPN domains are largely a-heli-
cal: HEPN1 is made of 12 linearly con-
nected a helices with flexible loops in
between the helices. HEPN2 is
composed of nine a helices, several
short b strands, and a b-hairpin with
charged residues at the tip, which points
toward the active site pocket. HEPN2
rests on HEPN1 such that the active
site residues (R1068, N1069, H1073
and R156, N157, H161, respectively)
are assembled into a canonical HEPN
active site, despite being at the N- and
C-terminal extremities of the linear pro-
tein (Figure 1) (Liu et al., 2017a, 2017b;
Sheppard et al., 2016; Smargon et al.,
2017). The HEPN1 domain is connected
to the Helical-1 domain by a highly
conserved inter-domain linker (IDL) that
reaches across the center of a large,
positively charged inner channel (Fig-
ure 1; Figure S1).Helical-1 is broken up linearly into three segments by the
Helical-2 and Lid domains, and makes extensive sugar-phos-
phate and nucleobase contacts with the direct repeat RNA
(Figure 2). Helical-1 also makes minor interface contacts
with both HEPN1/2 and the Lid domains. The Lid domain is
a mixed a and b secondary structure and caps the 30 free
end of the direct repeat RNA with two charged b-hairpins.
The longer of the two b-hairpins reaches across the RNA
loop to contact the Helical-1 domain, forming a lid over the
free crRNA ends. Positively charged residues from the
Lid domain point into a large central channel running
through the center of the protein (Figure 1; Figure S1). A
side channel penetrating from the outer solvent to the inner
channel is formed between a disordered loop (K431 to T438)
of the Lid domain and the two HEPN domains (Figure S1).
The Helical-2 domain is made of 11 a helices and wraps
under the body of the direct repeat RNA via its connection
Table 1. Data Collection and Refinement Statistics of PbuCas13b in Complex with RNA
Data Name PbuCas13b-Se: Peak PbuCas13b-Se: Inflection PbuCas13b-Se: Remote PbuCas13b: Native
Ligand citrate citrate citrate citrate
Data collection
Space group P212121 P212121 P212121 P212121
Cell dimensions
a, b, c (A˚) 90.82, 124.65, 140.73 90.86, 124.72, 140.77 90.88, 124.76, 140.79 90.82, 124.65, 140.73
a, b, g () 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90
Wavelength (A˚) 0.97934 0.97958 0.97204 1.03320
Resolution (A˚) 140.73 to 2.32
(2.47 to 2.32)a
140.77 to 2.35
(2.53 to 2.35)a
140.79 to 2.40
(2.62 to 2.40)a
43.9 to 1.65
(1.71 to 1.65)a
No. of unique reflections 59,325 55,600 50,274 191,617
Rsym 0.203 (1.73)
a 0.207 (1.69)a 0.214 (1.74)a 0.118 (2.89)a
Rpim 0.057 (0.494)
a 0.058 (0.474)a 0.060 (0.490)a 0.029 (1.028)a
I/s(I) 10.2 (1.4)a 10.4 (1.5)a 10.1 (1.5)a 11.5 (0.57)a
CC1/2 0.996 (0.7)a 0.996 (0.710)a 0.996 (0.706)a 0.998 (0.258)a
Completeness (%) 94.2 (55.8)a 94.0 (56.6)a 93.8 (52.0)a 99.9 (99.2)
Redundancy 13.6 (12.3)a 13.5 (12.5)a 13.5 (12.7)a 13.3 (10.7)a
Refinement
No. of reflections used — — — 191,463
Rwork/Rfree
b — — — 0.1532/0.1850
No. of atoms
Protein — — — 16,794
RNA — — — 1,175
Citrate — — — 126
Water — — — 866
Wilson B-factor — — — 31.02
B-factors (A˚2)
Protein — — — 46
RNA — — — 35
Citrate — — — 57
Water — — — 48
Root mean square (RMS) deviations
Bond lengths (A˚) — — — 0.013
Bond angles () — — — 1.36
Rotamer outliers — — — 2.85
Ramachandran analysisc (%)
Favored — — — 97.88
Allowed — — — 2.02
Outliers — — — 0.10
aHighest resolution shell is shown in parentheses.
bRfree was calculated with 5% of the data.
cDistribution of dihedral angles in Ramachandran diagram was calculated with MolProbity program (1).
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Figure 2. Map of crRNA-Protein Contacts in
PbuCas13b
A schematic diagram of the intermolecular con-
tacts between PbuCas13b amino acids and
crRNA bases.to Helical-1. Helical-2 interfaces extensively with the HEPN1
domain and makes minor contacts with the extended
b-hairpin of the Lid domain. A second positively charged
side channel oppositely oriented from the Lid domain
between Helical-1 and Helical-2 provides bulk solvent
accessibility to the crRNA in the unbound state (Figures S1A
and S1B).3744 Cell Reports 26, 3741–3751, March 26, 2019crRNA Hydrogen Bonding
Regulates Cas13b Nuclease
Activity
The direct repeat of the crRNA forms a
hairpin loop that is recognized by a
network of protein interactions from
highly conserved residues within the
Helical-2 domain (Figures 2 and 3A).
K870 coordinates with O4 from both
U(16) and U(19), which indirectly flips
U(17) into the solvent at the hairpin
turn, with no visible residue contacts.
W842 stacks with the nucleobase of
U(18) while also interacting with the
phosphate backbone together with
K846. R877 and E873 further stabilize
U(18) through interactions with
base N3 and O2 positions. R874 and
R762 stabilize the U20 position through
sugar O40 and base O20 interactions,
respectively.
Electron density for all RNA bases
enabled complete model building of the
direct repeat RNA. The direct repeat is
mostly buried between the two Helical
domains and the Lid domain but pro-
trudes slightly into the solvent from
Helical-1, explaining how Cas13b is
able to utilize alternate, longer crRNAs
that would extend the RNA hairpin
length. The overall crRNA structure is a
deformed A-form duplex comprising a
stem [bases G(1)–G(4), C(33)–
C(36)], loop [C(5)–U(8), A(29)–
A(32)], stem [U(9)–U(14), A(23)–
A(28)], bulge [C(15), G(21)], and
hairpin loop [U(16)–U(20)] architec-
ture (Figures 2 and 3B; Figures S2I–
S2N). Helical-1 and Helical-2 mediate
direct and indirect recognition of the
crRNA hairpin together with the Lid
domain, which caps the 30 free end.
Three bases, C(8), U(20), andA(29), are flipped out from the body of the RNA. The back-
bone carbonyl of T754 stabilizes the flipped-out, highly
conserved C(8) base by interacting with the base N4 amine,
holding the base in a hydrophobic pocket of highly conserved
residues (Y540, 566–571, K751, 753–761) in the Helical-1 and
Helical-2 domains. The base flip is further stabilized by interac-
tion between the C(8) N30 and the sugar (O20) of U(7).
A B
C D
Figure 3. PbuCas13b crRNA Recognition and Processing
(A) Diagram of crRNA substrate co-crystallized with PbuCas13b. Direct repeat nucleotides are colored red and spacer nucleotides in light blue (full spacer is not
shown). Watson-Crick base-pairing is denoted by black lines; non-Watson-Crick base-pairing is denoted by gray lines.
(B) The structure of crRNA within the crystallized PbuCas13b complex. The coloring is consistent with (A), and individual bases are numbered (1 to 36 in the
crRNA, 1 for spacer).
(C) Model of the 30 end of the crRNA showing the catalytic residue K393 of the crRNA processing site and additional PbuCas13b residues that coordinate the
crRNA.
(D) Analysis of Lid domain residues predicted to coordinate and process crRNAwithin PbuCas13b. Right: schematic shows Cas13b-mediated RNA degradation.
The top shows collateral RNase activity in fluorescent collateral RNA-cleavage assays with Lid domain mutants (asterisk indicates nearly undetectable levels of
fluorescence); the bottom shows processing of crRNA by these mutants. Cartoons of the expected cleavage products are shown to the left of the gel; cleavage
bands and expected sizes are indicated by red triangles to the right of the gel.Changing C(8) to G or U decreases nuclease activity and de-
stabilizes the protein-RNA complex, as measured in a thermal
stability assay (Figure S2P). U(20) is absolutely conserved in
Cas13b direct repeat sequences (Figure S2O) and is coordi-
nated by completely conserved residues, most notably R762,
which makes contacts with the nucleobase O2, and R874,
which intercalates between G(21) and U(20), holding the
base out and making contacts with the U(20) sugar O40.
Mutating U(20) to G decreases nuclease activity (Figure S2P).
In contrast with C(8) and U(20), A(29) is not conserved in
Cas13b direct repeat sequences, and the nucleobase is not co-
ordinated by any amino acids. Instead, A(29) engages in mul-
tiplete base-pairing with G(26) and C(11) (Figures S2K–S2M)
(Lu et al., 2015). A(29) is tolerant to identity changes to any
other base (Figure S2P). Base changes that decrease the ther-
mal stability of the Cas13+crRNA complex also decrease gen-
eral nuclease activity. Furthermore, stabilizing the RNA hairpin
by changing the wobble base pair between U(27) and
G(10) to a Watson-Crick base pair increases general nucleaseactivity (Figure S2P). The hairpin loop distal end of the crRNA
(1 to 4 and 33 to 36) is helical and recognized by a com-
bination of base and backbone interactions (Figure 2). Notably,
N653 and N652 make critical minor groove direct contacts with
U(2) and C(36), and coordinate the 50 and 30 ends of the
hairpin (Figure 3C). Disruption of these base identities or muta-
tion of N653 or N652 to alanine substantially decreases Cas13b
activity in vitro and in mammalian interference assays (Fig-
ure 3D; Figures S2A, S2D, and S2P). C(33) is coordinated
by N756 via the nucleobase O2 and sugar O20, and changing
this C to A or G abrogates general RNase activity and de-
creases protein stability (Figure 2; Figure S2P). The crRNA
hairpin end (nucleotides 17 to 20) is stabilized by extensive
phosphate backbone hydrogen bonding and base interactions
(Figure 2). Mutating U(18) to G abolishes general nuclease ac-
tivity. U(19) and U(20) are also intolerant of G mutations,
although other base mutations are tolerated. This suggests
that the G O6 or N2 nucleobase atoms disrupt nuclease activity
(Figure S2P).Cell Reports 26, 3741–3751, March 26, 2019 3745
Cas13b Processes Pre-crRNA into Mature crRNA Using
a Second Nuclease Site
Several class 2 CRISPR systems process long pre-crRNAs into
mature crRNAs (East-Seletsky et al., 2016; Fonfara et al., 2016;
Smargon et al., 2017). Cas13b has been shown to process its
own crRNA at the 30 end (Smargon et al., 2017). A number of
highly conserved residues are in contact with or nearby the 30
end of the RNA and potentially form a second, non-HEPN
nuclease site (Figures 2 and 3C). We mutated to alanine six
conserved residues (K393, R402, N480, R482, N652, and
N653) nearby the 30 RNA end and tested these mutants for
crRNA processing and target-activated collateral nuclease ac-
tivity (Figure 3D; Figures S2A–S2D). K393 when mutated to
alanine abrogates RNA processing but retains targeted nuclease
activity, confirming the location of a second nuclease site in the
Lid domain responsible for crRNA processing (Figures 3C and
3D; Figures S2A–S2D).
Mechanism of RNA Targeting
The crRNA is buried within the Cas13b protein in the crystal
structure and is inaccessible to solvent. Therefore, hybridization
of crRNA to target RNA requires a major protein conformation
change allowing the target RNA to enter the Cas13b central cav-
ity. The only sterically permissible route from solvent to central
channel is between theHEPN1 andHelical-2 domains, indicating
the two domains must open to allow target RNA to hybridize with
the crRNA. Loops bearing charged amino acids are poised to
escort nucleic acid from the solvent into the central channel via
this route, which is supported by the finding that mutagenesis
of these residues decreases RNA knockdown efficiency (Fig-
ure S2H). Mutation of residue D397 on a Lid domain b-hairpin
far from the predicted RNA binding pocket but at the interface
between HEPN1 and Helical-2 also resulted in decreased RNA
knockdown (Figure S2H). To see if residue D397 is also involved
in RNA targeting, we tested this mutant with REPAIR RNA edit-
ing, which relies on successful targeting of Cas13b to RNA but
does not require nuclease activity (Cox et al., 2017). As ex-
pected, this mutation resulted in a dramatic decrease in RNA ed-
iting, suggesting a loss of PbuCas13b targeting and implicating
the b-hairpin of the Lid domain in directing the RNA into the cen-
tral channel (Figure S3E).
To further understand the mechanism of RNA targeting, we
used a thermal denaturation assay to analyze changes in
hydrogen bonding caused by altering PbuCas13b conforma-
tions (Figures S3G–S3I). Addition of target RNA to crRNA-bound
PbuCas13b shifts the melting curve to a bimodal curve less
stable than the binary crRNA-bound PbuCas13b complex,
consistent with the structurally predicted central channel
entrance between the HEPN1 and Helical domains (Figures
S3G–S3I). The destabilization effect was also seen by limited
proteolysis; PbuCas13b in the presence of target RNA was
noticeably more susceptible to proteolysis by pepsin and
chymotrypsin than with crRNA only (Figure S3J). We posited
that the lower Tm curve represents the open conformation of
Cas13b as it probes target RNA, whereas the more stable
target-bound curve represents the closed state. To test this,
we titrated target RNA to the Cas13b-crRNA complex. As ex-
pected, lower molar ratios of target RNA decrease the presence3746 Cell Reports 26, 3741–3751, March 26, 2019of the lower Tm curve, suggesting the alternate conformation of
Cas13b is target dependent and may correspond to the pre-
dicted state with an opening between the HEPN1 and Helical do-
mains (Figure S3K). Such an open conformation may actively
chaperone target RNA from the solvent to the central channel af-
ter initial recognition of target RNA by crRNA. If so, we reasoned
that partially matched RNA in the region responsible for initiating
the conformational changewould induce a corresponding partial
decrease in thermal stability. We designed a target RNA with a
mismatched 30 half and repeated the melting experiments to
test this hypothesis (Figure 4A). Target RNA with a 30 half mis-
matched, but not other variants, partially shifted the Tm curve
to the target-bound conformation, indicating that the 30 side of
the spacer sequence initiates target recognition, most likely
causing an opening between the HEPN1 and Helical-2 domains.
Specificity and RNA Interactions within the Central
Channel
We hypothesized that the target RNA enters the central channel,
and that the contacts with the protein are tighter at the 50 end of
the target andmore open at the 30 end (Figure 5C). If true, it would
suggest that flexibility within the central channel is linked to the
specificity of target binding and collateral activation. To identify
the single base mismatch sensitivities along the length of
PbuCas13b crRNA, we made single base mutations at each po-
sition along the spacer and tested their potential to activate gen-
eral nuclease activity (Figure 4B). As expected, the 30 side of the
crRNA spacer (positions 1–11), which is less tightly bound within
the central channel, is tolerant of mismatches and even has
increased activity with mismatches at some positions in the
open part of the central channel. The narrowest region of the
central channel, which corresponds to spacer positions 12–17,
showed no detectable nuclease activity with single mismatches.
Tandem mismatches are not tolerated along the length of the
spacer, with the exception of slight tolerance at the first and sec-
ond positions, where the central channel is least constricted
(data not shown). However, in denaturation assays, tandemmis-
matches between spacer and target did not lead to deviation
from wild-type curves, indicating that targeting occurs prior to
proofreading within the central channel (Figure 4A). Taken
together, these results suggest a model where crRNA-bound
Cas13b initially probes the 30 end of target RNA. If complemen-
tarity is found, the HEPN1 and Helical-2 domains open to enable
access to the positively charged central channel within the pro-
tein, and the rest of the RNA is hybridized (Figure 5A). The
bimodal thermal melting curves may reflect the target being
repeatedly bound and released, as well as present in several
conformations in solution (Figure 5B). If binding is reversible,
this also suggests a multi-turnover mechanism. Michaelis-
Menten kinetics of PbuCas13b cleavage showed that indeed
PbuCas13b is multi-turnover (987 turnovers/s) (Figure 5D).
Taken together, these results establish a structural model for
the mechanism for RNA targeting by Cas13b (Figure 5A).
Structure-Guided Engineering of Cas13b RNA Cleavage
Specificity
Cas13 proteins have preference for cleaving specific dinucle-
otide RNA sequences (East-Seletsky et al., 2017; Gootenberg
Figure 4. Biochemical Characterization of
RNA Targeting by Cas13b
(A) Thermal melting curves of PbuCas13b com-
plexed with crRNA and target RNA. To the right of
the curves are cartoons of the substrate used with
red lines indicating mismatches (tandem mis-
matches are shown on the left; larger mismatches
are shown on the right). Curves shifted to the left
indicate a destabilized complex.
(B) The effect of single-nucleotide mismatches
between target and crRNA spacer on collateral
nuclease activity activation in fluorescent collat-
eral RNA-cleavage assays. Two different guide
sequences (upper, guide 1; lower, guide 2) are
shown.
(C) Dinucleotide cleavage preferences measured
via fluorescent collateral RNA-cleavage assays
using wild-type PbuCas13b (gray) and
PbuCas13b loop 938–951 swapped with the
corresponding loop from PgiCas13b (Pbu:
PgiCas13b, purple). See also Figure S5A.
(D) Diagram of the active site of PbuCas13b in
the crystal structure. Citrate (shown in yellow) is
bound in the active site, and loop 938–951 is
shown in the lower left labeled as ‘‘Loop.’’et al., 2018). We predicted that a b-hairpin loop (residues
938–951) positioned near the active site regulates RNA cleav-
age preferences (Figure 4D; Figure S4). The identities of the
residues in this active site proximal loop and the size of it
are variable, but this loop is present within most known
Cas13bs and positioned between highly conserved residues
of the b strands (Figure S4C; Data S1). To test the involvement
of this loop in RNA cleavage specificity, we either deleted
the loop or swapped it with amino acid loop sequences
from other Cas13b orthologs to see if these mutations
altered dinucleotide cleavage preference. The loop deletion
mutant did not have any RNase activity. However, cleavage
preferences for five of the nine loop swaps that retained activ-
ity had altered dinucleotide cleavage preferences, and three
mutants had increased UU cleavage preference, demon-
strating a role for this loop in cleavage activity and nucleotide
recognition (Figures S4A and S4B). The ability to alter
cleavage specificity will enable expansion of nuclease-
based assays such as SHERLOCK (Gootenberg et al., 2017,
2018).Cell RepA General Strategy for Truncation
of Cas13b for AAV Packaging
AAV-mediated delivery is commonly used
for gene therapies, but REPAIR exceeds
the size limit of AAV’s cargo capacity
(Cox et al., 2017; Wu et al., 2010).
Because HEPN2 appears to be signifi-
cantly less integrated into the overall
structure than the other domains, we
reasoned that a Cas13b enzyme with
HEPN2 removedwould retain RNA target-
ing activity for base editing. We showed
previously that C-terminal truncations ofPrevotella sp. P5-125 (PspCas13b) did not decrease REPAIR ac-
tivity, consistent with the idea that the HEPN2 domain is not crit-
ical (Cox et al., 2017). For additional validation, we used another
ortholog of Cas13b, from Porphyromonas gulae (PguCas13b),
which is stably expressed and shows high activity in mammalian
cells, in contrast with PbuCas13b. Based on alignments between
PbuCas13b and PguCas13b, wemade truncations to remove the
HEPN2domain, fused it to ADAR, and tested its ability to carry out
base editing with the REPAIR system. Not only did these trun-
cated mutants retain RNA targeting, some were significantly
more efficient at RNA editing, suggesting improved RNA binding
(Figure S5A). HEPN2 partially obstructs this side channel, which
may explain how deletion of HEPN2 improves RNA editing effi-
ciency by enabling more sterically favorable binding.
Cas13b Is Structurally andMechanistically Distinct from
Other CRISPR Nucleases
Lastly, we compared Cas13b with the structure of Cas13a and
Cas13d (Figure 6) (Liu et al., 2017a; Zhang et al., 2018). Despite
functional similarities between these family members, there areorts 26, 3741–3751, March 26, 2019 3747
Figure 5. Structural Mechanism of RNA Tar-
geting by Cas13b
(A) A cartoon depicting the predicted dynamics of
Cas13b. HEPN1 (blue oval) opens to accept the
target RNA (gray) into the central channel, which
then base pairs with the guide RNA (blue). HEPN1
then closes, and cleavage occurs in a divalent
metal ion-dependent fashion. Hel-2, Helical-2.
(B) Thermal denaturation data showing bimodal
curve shift in response to target RNA binding.
(C) Model of PbuCas13b crystal structure with
ideal A-form RNA docked into the central channel.
(D) Kinetics data measuring turnover rate of
PbuCas13b nuclease activity in fluorescent
collateral RNA-cleavage assays (987 turnovers/s).no identifiable structural similarities between PbuCas13b and
other nucleases beyond the active site architecture. However,
an SAS search provided a match to the crystal structure of
LbCas12a (previously referred to as LbCpf1) and highlighted a
bridge helix-like sub-domain within Cas13b (Figures S5B–S5D)
(Milburn et al., 1998). Although this domain is poorly conserved
within the Cas13b family, it appears to be a common structural
feature with Cas12a that mediates essential nucleic acid con-
tacts. Given the fundamental differences between Cas13b and
Cas12a, we postulate that the bridge helix arose as a convergent
feature and does not indicate a common ancestor for these two
proteins. Nonetheless, we refer to this feature as the bridge helix
for consistency with the nomenclature of other class 2 effectors
(Shmakov et al., 2015; Yamano et al., 2016). Finally, to identify
similarities to other domains in the PDB, the complete
PbuCas13b structure, as well as isolated domains, was queried
using the DALI server (Holm and Laakso, 2016). HEPN1matched
to the HEPN2 domain of LshCas13a, but no other domains, had
notable similarity (Liu et al., 2017a).
DISCUSSION
The recent discovery of the Cas13 family of single-effector RNA-
guided RNases has led to their rapid development as tools for
manipulation of the mammalian genome, as well as for the
detection of nucleic acids. To date, four distinct Cas13 subtypes
have been distinguished, Cas13a–d, of which Cas13a, Cas13b,
and Cas13d have been characterized. These three subtypes
share a number of features, such as crRNA processing and
non-specific nuclease activity under some conditions following
target recognition. However, there are clear differences between
these enzymes,most notably at the structural level. For example,
Cas13a and Cas13d share linear domain organization and over-
all structural similarities, whereas we show here that Cas13b is
structurally and mechanistically distinct.3748 Cell Reports 26, 3741–3751, March 26, 2019One of themajor aspects of the Cas13b
structure that distinguishes it from previ-
ously reported structures of Cas13a and
Cas13d is the manner in which the target
RNA is engaged. In Cas13a and Cas13d,
there is a shared solvent-exposed cleft
that grasps the target RNA. By contrast,PbuCas13b opens up to allow target RNA access to the central
channel. This suggests that the target probing dynamics are sub-
stantially different between these subtypes; whereas in Cas13a
and Cas13d, the target binding cleft is persistently open (Liu
et al., 2017a; Zhang et al., 2018), there is a conformational
change in Cas13b that must precede target RNA binding. It will
be interesting to determine whether these mechanistic differ-
ences contribute to different enzymatic kinetics.
PbuCas13b nuclease activity is preferentially activatedbyRNA
sequences with a protospacer flanking site (PFS) that can be any
nucleotide other than C at the 50 and a slight AA preference at the
30 of the target (Cox et al., 2017; Smargon et al., 2017). The 50 PFS
nucleotides in our model of RNA binding protrude into the sol-
vent, out of range for protein contacts, and therefore it is not sur-
prising that targeting initiates at the 30 preferential nucleotides,
which are in range to make protein contacts. Higher-resolution
structures of the target-bound complex, as well as investigations
into secondary structure of the RNA, may provide deeper insight
into why the 50 PFS confers preferential nuclease activation.
Initial studies of Cas13 enzymes also revealedwide variation in
the nucleotide cleavage preference among orthologs (Gooten-
berg et al., 2018). PbuCas13b shows a UU cleavage preference,
which we show here can be reengineered by manipulating a sin-
gle loop near the active site. Although no comparable loop on
Cas13a or Cas13d is immediately apparent, further exploration
of the protein region surrounding the active site may enable en-
gineering of these systems with a similar mutagenic strategy.
The structure of PbuCas13b provides new information on the
diversity of the type VI protein family and highlights the substan-
tial differences between Cas13b and other CRISPR systems.We
show the structural basis for crRNA recognition and processing,
and reveal key regulators of nuclease activity in both the guide
RNA and protein. Our data suggest a dynamic targeting system
that actively escorts the target RNA into the positively charged
central channel by adopting an open configuration between
Figure 6. Comparison of Cas13b with
Cas13a and Cas13d
(A) Comparison of the linear domain organization
of PbuCas13b, LshCas13a, and EsCas13d. crRNA
cartoons are shown to the right depicting archi-
tectural differences between type VI systems.
Hel-1, Helical-1; HEP, HEPN; NTD, N-terminal
domain.
(B–D) Two views of PbuCas13b (B), LshCas13a
(PDB: 5WTK) (C), and EsCas13d (PDB: 6E9E) (D)
rotated 90 degrees. Insets show active site resi-
dues oriented with catalytic residues aligned.the HEPN and Helical domains. Based on our structures of
PbuCas13b, we identified important features that regulate RNA
targeting and cleavage preference. Insights from this work will
enable further rational engineering to improve functionality for
RNA targeting specificity, base editing, and new enzymatic tools
for nucleic acid detection (Cox et al., 2017; Gao et al., 2017; Goo-
tenberg et al., 2018; Slaymaker et al., 2016).
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
HEK293FT Cells
Mammalian cell culture experiments were performed in the HEK293FT line (American Type Culture Collection (ATCC)), which was
grown in Dulbecco’sModified EagleMediumwith high glucose, sodium pyruvate, andGlutaMAX (Thermo Fisher Scientific), addition-
ally supplemented with 1x penicillin–streptomycin (Thermo Fisher Scientific) and 10% fetal bovine serum (VWRSeradigm). The sex of
HEK293FT cells is female.
BL21 (DE3) Cells
BL21 (DE3) cells were purchased from New England Biolabs.
METHOD DETAILS
Protein Purification for Crystallization
PbuCas13b was expressed in a pET28 based vector with a twin-strep-sumo tag fused at the N-terminal in chemically competent
BL21 (DE3) cells purchased from New England Biolabs. Cells with the expression plasmid were grown at 37C to OD 0.2, then
the temperature was switched to 21C. Growth continued until OD600 was 0.6, then cells were induced with 5 mM IPTG. Cultures
were grown for 18-20 hours, and then cells were harvested by centrifugation at 5,000 rpm and frozen at 80C. Frozen cell paste
was homogenized in Buffer A (500 mM sodium chloride, 50 mM HEPES pH 7.5, 2 mMDTT) supplemented with benzonase and lyso-
zyme. The cells were broken by two passes through a microfluidizer at 20,000 psi and cell debris was separated from the soluble
fraction by centrifugation at 10,000 rpm. The soluble fraction was passed through Streptactin resin (GE life sciences) and washed
with 10 column volumes of Buffer A, followed by 10 column volumes of wash buffer (1 M NaCl, 50 mM HEPES pH 7.5, 2 mM
DTT), and finally by 10 column volumes of cleavage buffer (400 mMNaCl, 20 mMHEPES pH 7.5, 2 mMDTT). PbuCas13b was eluted
from the resin by addition of 5 mM desthiobiotin (Sigma), then cleaved overnight by sumo protease after being supplemented with
20 mM DTT. After cleavage the protein was passed through a Heparin column, concentrated to 500 mL, and passed over a superdex
200 column (GE life sciences) equilibrated in storage buffer (500 mM NaCl, 10 mM HEPES pH 7.0, 2 mM DTT). Peak fractions were
pooled and concentrated to at least 20 mg/ml. Seleno-methionine protein was similarly purified except with 5 mM DTT being sup-
plemented in each buffer. Protein was quantified using Pierce reagent (Thermo).
Crystallization and Data Collection
RNA substrate was added to PbuCas13b protein at 2:1 molar ratio and dialyzed for 7 hours against dialysis buffer (50 mM NaCl,
10 mM HEPES pH 7.0, 2 mM TCEP). Complexed PbuCas13b+RNA was diluted to 10 mg/ml with dialysis buffer and set up at
20C by hanging drop vapor diffusion against 165mM sodium citrate pH 4.6, 5.5%PEG6000, and 2mM TCEP at varying drop ratios.
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buffer (140 mM sodium citrate pH 4.6, 5% PEG6000, 35% PEG400), soaked for up to 24 hours, then flash cooled in liquid nitrogen.
Selenium crystals for phasing were grown in similar conditions supplemented with 5 mM TCEP.
Native diffraction data from crystals of PbuCas13b and guide RNA were collected at the Advanced Photon Source, Argonne Na-
tional Labs on beamlines 23-ID-B/D, and anomalous data at the Diamond light source on beamline I04. A small beamwas used, either
collimated (23-ID) or focused (Diamond) to 20m, andmultiple datasets were collected along the length of the crystal. Anomalous data-
sets were collected at 0.97934 A˚ (peak), 0.97958 A˚ (inflection) and 0.97204 A˚ (remote) wavelengths. Diffraction data were processed
using XDS (Kabsch, 2010a; 2010b) and scaled in aimless (Evans andMurshudov, 2013) implemented in autoPROC toolbox (Vonrhein
et al., 2011). The statistics are summarized in Table 1.
Crystal Structure Solution
The crystal structure of PbuCas13b was solved by multiwavelength anomalous diffraction (MAD) using selenium as anomalous scat-
tering. The position of 27 SeMet sites were determined and refined using phenix.autosol (Adams et al., 2010; Terwilliger et al., 2009).
A partial model was built by phenix.autobuild (Terwilliger et al., 2008) using a 3.5 A˚ resolution experimental map with a figure of merit
of 0.35. Cycles of manual rebuilding in Coot (Emsley et al., 2010; Emsley and Cowtan, 2004) and refinement in phenix.refine (Afonine
et al., 2012; Echols et al., 2014; Zwart et al., 2008) were done using the selenium experimental map. R-free flags and experimental
phases were transferred from the selenium data to high-resolution native data using reflection file editor in PHENIX. These reflections
wereused for further cyclesof rebuilding inCoot and refinement inphenix.refine.Anomalousdifferencemapswere usedensurecorrect
registry. Refinement in phenix.refine used TLS (translation, libration, and screw), positional, and individual B-factor refinement. Citrate
geometry restraints were generated by phenix.elbow (Moriarty et al., 2009). The final model contains one polypeptide chain, one RNA
nucleotide chain, seven citratesmolecules, four tetraethylene glycol (PG4) molecule, twoCl atoms, twoNa atoms, and 866water mol-
ecules. Figures were created with PyMOL Software (The PyMOL Molecular Graphics System, Version 1.8 Schro¨dinger, LLC.).
Structure Analysis
RNA structure was analyzed using DSSR (Lu et al., 2015). Protein conservation mapping to the structure was done using the Consurf
server (Ashkenazy et al., 2016). Protein secondary structure was analyzed using the PDBSUM webserver (de Beer et al., 2014) (Fig-
ure S1E). APBS as part of the PyMOL visualization program was used to calculate electrostatics (Jurrus et al., 2018). Structure vali-
dation statistics were generated with MolProbity (Chen et al., 2010)
Protein Alignment
Alignments of Cas13b enzymes were done using ClustalW or Muscle as implemented in Geneious (Ripma et al., 2014). Neighbor-
joining trees were generated using a Jukes-Cantor distance model. Conservation alignments for structure analysis were done on a
tree subgroup that successfully matchedHEPNdomain active site residues to other familymembers (Figures S5B–S5D andData S1).
Gel Filtration Experiments
For formation of guide complex, 100 mg of PbuCas13b were incubated with two molar equivalents of guide RNA for 20 minutes at
room temperature, in 100 mL of buffer (125 mM NaCl, 10 mM HEPES pH 7.0, 2 mM TCEP). For formation of guide-target complex,
100 mg of PbuCas13b and two molar equivalents of guide RNA were incubated together for 20 minutes as above. Two molar equiv-
alents of target RNAwere then added to the solution and themixture was incubated at room temperature for an additional 20minutes
(100 mL total volume, 125 mM NaCl, 10 mM HEPES pH 7.0, 2 mM TCEP). Apo protein was similarly diluted to 1 mg/mL in a buffer so-
lution of 125mMNaCl, 10mMHEPES pH7.0, 2mMTCEP. Sampleswere injected from a 2mL capillary loop onto aGESuperdex 200
Increase 10/300 GL column and run with 500 mM NaCl, 10 mM HEPES pH 7.0, 2 mM DTT buffer (Figure S6E).
ThermoFluor Melting Assay
ThermoFluor melting assays were adapted from a previously published protocol (Huynh and Partch, 2015). Samples were prepared
to a final volume of 20 mL with 1 mg of PbuCas13b (apo, guide, or guide-target complex, as prepared above) in a solution with a final
concentration of 50 mMNaCl, 10 mMHEPES pH 7.0, 6.25x SYPROTMOrange Dye. For MgCl2 cleavage and binding experiments, a
final concentration of 6 mMMg2+ was added to the buffer mix described. For control experiments with non-complementary RNA, 2
molar equivalents of RNA were incubated with the protein complex. Melting experiments were conducted in triplicate on a Roche
LightCycler 480 II.
Limited Proteolysis
For limited proteolysis experiments, 10 mg of PbuCas13b were incubated with 2 molar excess crRNA or crRNA and target for 30 min
at room temperature. 400 mg of protease (buffer, trypsin, chymotrypsin or pepsin) were added, and themix was incubated for 5min at
37C, then placed quickly on ice for 2 min before adding SDS loading buffer and running on a 4%–12% acrylamide gel.
Protein Expression and Purification of PbuCas13b Pre-crRNA Processing Mutants
Alanine mutants at each of the putative crRNA-processing catalytic residues were generated using PIPE-site-directed mutagenesis
cloning from the TwinStrep-SUMO-PbuCas13b expression plasmid and transformed into BL21(DE3)pLysE E. coli cells. For eache3 Cell Reports 26, 3741–3751.e1–e5, March 26, 2019
mutant, 2 L of Terrific Broth media (12 g/L tryptone, 24 g/L yeast extract, 9.4 g/L K2HPO, 2.2 g/L KH2PO4), supplemented with
100 mg/mL ampicillin, was inoculated with 15 mL of overnight starter culture and grown until OD600 0.4 0.6. Protein expression
was induced with the addition of 0.5mM IPTG and carried out for 16 hours at 21Cwith 250 RPM shaking speed. Cells were collected
by centrifugation at 5,000 RPM for 10 minutes, and paste was directly used for protein purification (10-20 g total cell paste). For lysis,
bacterial paste was resuspended via stirring at 4C in 50 mL of lysis buffer (50 mM Tris-HCl pH 7.5, 500 mM NaCl, 1mM DTT) sup-
plementedwith 50mg Lysozyme, 1 tablet of protease inhibitors (cOmplete, EDTA-free, RocheDiagnostics Corporation), and 500Uof
Benzonase (Sigma). The suspension was passed through a LM20 microfluidizer at 25,000 psi, and lysate was cleared by centrifuga-
tion at 10,000 RPM, 4C for 1 hour. Lysate was incubated with 2 mL of StrepTactin superflow resin (QIAGEN) for 2 hours at 4C on a
rotary shaker. Resin bound with protein was washed three times with 10 mL of lysis buffer, followed by addition of 50 mL SUMO pro-
tease (in house) in 20 mL of IGEPAL lysis buffer (0.2% IGEPAL). Cleavage of the SUMO tag and release of native protein was carried
out overnight at 4C in Econo-column chromatography column under gentle mixing on a table shaker. Cleaved protein was collected
as flow-through, washed three times with 5 mL of lysis buffer, and checked on a SDS-PAGE gel.
Protein was diluted two-fold with ion exchange buffer A containing no salt (50 mM Tris-HCl pH 7.5, 1mM DTT) to get the
starting NaCl concentration of 250 mM. Protein was then loaded onto a 5 mL Heparin HP column (GE Healthcare Life Sciences)
and eluted over a NaCl gradient from 250 mM to 1 M. Fractions of eluted protein (at roughly 700 mM) were analyzed by SDS-
PAGE gel and Coomassie staining, pooled and concentrated to 1mL using 50 MWCO centrifugal filters (Amicon). Concentrated pro-
tein was loaded onto a pre-equilibrated size exclusion column and eluted using S200 buffer containing 50 mM Tris-HCl pH 7.5,
500 mM NaCl, 2mM DTT. Monodisperse protein fractions were analyzed by SDS-PAGE gel and Coomassie staining, followed by
concentrating and buffer exchange into protein storage buffer (600 mM NaCl, 50 mM Tris-HCl pH 7.5, 1 mM DTT).
Pre-crRNA Processing Assays
RNA for pre-crRNA processing and nuclease assays were ordered as Ultramers (IDT) and in vitro transcribed using the HiScribe T7
Quick High Yield RNA Synthesis kit (New England Biolabs). RNA was purified with AmpureXP RNA clean up beads and stored
at 20C for further use. For testing pre-crRNA processing, wild-type and mutant protein were incubated with pre-crRNA at four
times molar excess of protein relative to the RNA. Pre-crRNA processing was carried out in Cas13b crRNA processing buffer
(10 mM TrisHCl pH 7.5, 50 mM NaCl, 0.5 mM MgCl2, 20U SUPERase in (ThermoFisher Scientific), 0.1% BSA) for 30 minutes at
37C, stopped by adding 2x TBE-Urea gel loading buffer and denatured for 5 minutes at 95C. Samples were immediately put on
ice for 10 minutes before running them on an 15% TBE-Urea gel in 1x TBE buffer at 200 V for 40 minutes. Gel staining was carried
out in 1x Sybr Gold in 1x TBE for 15 minutes and imaged on a BioRad gel doc system.
Fluorescent Collateral RNA-Cleavage Assay for Pre-crRNA Mutants
Detection assays were carried out as quadruplicates with equimolar ratios of PbuCas13b or PbuCas13b mutants, crRNA, and RNA
target, in nuclease assay buffer (20 mMHEPES, 60 mMNaCl, 6 mMMgCl2, pH 6.8) with 0.5 mL murine RNase inhibitor (New England
Biolabs) and 125 nM of poly-U homopolymer RNA sensor (Trilink). Samples were incubated for 3 hours at 37C on a fluorescent plate
reader equipped with a FAM filter set. Measurements were recorded at 5-minute intervals and data were normalized to the first time-
point.
Kinetics and Data Analysis
Varying amounts of activated protein complex (5 nM, 2 nM, and 1 nM) were diluted in a mixture containing murine RNase inhibitor
(New England Biolabs, 0.5 mL per 20 mL of reaction volume), 1 x CutSmart Buffer (New England Biolabs). Collateral cleavage
was commenced by the addition of a fluorescent RNA reporter (FAM-(rU) 6 -BHQ, TriLink) in a range of concentrations: 12.5 nM,
25 nM, 50 nM, 100 nM, 200 nM, 400 nM, 800 nM, 1600 nM, 3200 nM, and 6400 nM. Reactions (20 mL) were performed with four bio-
logical replicates on a 384-well plate (Corning) and fluorescence was measured at 150 s intervals on a fluorescence plate reader
(BioTek) for 180minutes. The first 20minutes of data at each substrate concentration was fitted by linear regression (GraphPad), and
the initial velocity (nM s1) was plotted against substrate concentration (nM). The data were fitted to the Michaelis-Menten equation
(GraphPad) in the form v = ðVmaxÞ½S=ðKm + ½SÞ where v is the velocity, Vmax is the maximum velocity, ½S is the substrate concentra-
tion, and Km is the Michaelis-Menten constant, or the substrate concentration at which v = 1=2Vmax.
Kcat was calculated by dividing the value obtained for Vmax by the enzyme concentration, and the three enzyme conditions (5 nM,
2 nM, and 1 nM of activated complex) were averaged to obtain a value of 987 turnovers per second.
Design and Cloning of Mammalian Constructs for RNA Editing
PguCas13bwasmade catalytically inactive (dPguCas13b) bymutating two arginine and two histidine residues in the catalytic sites of
the HEPN domains to alanine (R146A/H151A/R1116A/H1121A). These catalytically inactivated Cas13bs were Gibson cloned into
pcDNA-CMV vector backbones containing the deaminase domain of ADAR2(E488Q) fused to the C-terminal end of the Cas13b
via a GS linker (Cox et al., 2017). To generate truncated versions, primers were designed to PCR amplify the dCas13b that truncated
off 60 bp (20 amino acids) progressively up to 900 bp off of the C-terminal end (15 truncations in total), and these truncated Cas13bCell Reports 26, 3741–3751.e1–e5, March 26, 2019 e4
genes were Gibson cloned into the pcDNA-CMV-ADAR2 backbone described above. Guide RNAs targeting Cluc were cloned using
golden gate cloning into a mammalian expression vector containing the direct repeat sequence for this ortholog at the 30 end of the
spacer sequence destination site, under the U6 promoter.
The luciferase reporter used was a CMV-Cluc (W85X) EF1alpha-Gluc dual luciferase reporter used by Cox et. al. (2017) to measure
RNA editing. This reporter vector expresses functional Gluc as a normalization control, but a defective Cluc due to the addition of the
W85X pretermination site.
Mammalian Cell Culture
Mammalian cell culture experiments were performed in the HEK293FT line (American Type Culture Collection (ATCC)), which was
grown in Dulbecco’sModified EagleMediumwith high glucose, sodium pyruvate, andGlutaMAX (Thermo Fisher Scientific), addition-
ally supplemented with 1x penicillin–streptomycin (Thermo Fisher Scientific) and 10% fetal bovine serum (VWR Seradigm).
All transfections were performed with Lipofectamine 2000 (Thermo Fisher Scientific) in 96-well plates. Cells were plated at approx-
imately 20,000 cells/well 16-18 hours prior to transfection to ensure 90% confluency at the time of transfection. For each well on the
plate, transfection plasmids were combined with Opti-MEM I Reduced SerumMedium (Thermo Fisher) to a total of 25 ml. Separately,
24.5 ml of Opti-MEM was combined with 0.5 ml of Lipofectamine 2000. Plasmid and Lipofectamine solutions were then mixed and
pipetted onto cells.
RNA Knockdown in Mammalian Cells
To assess RNA targeting in mammalian cells with reporter constructs, 150 ng of Cas13 construct was co-transfected with 300 ng of
guide expression plasmid and 45 ng of the dual luciferase reporter construct. Forty-eight hours post-transfection, media containing
secreted luciferase was harvested and measured for activity with BioLux Cypridinia and Biolux Gaussia luciferase assay kits (New
England Biolabs) on a plate reader (Biotek Synergy H4) with an injection protocol. Signal from the targeted Gluc was normalized
to signal from un-targeted Cluc, and subsequently, experiments with PbCas13b mutant luciferase signal were normalized to exper-
iments with guide–only luciferase signal (the average of three bioreplicates). All replicates performed are biological replicates.
REPAIR Editing in Mammalian Cells
To assess REPAIR activity in mammalian cells, we transfected 150 ng of REPAIR vector, 300 ng of guide expression plasmid, and
45 ng of the RNA editing reporter. We then harvested media with the secreted luciferase after 48 hours and diluted the media 1:10 in
Dulbecco’s phosphate buffered saline (PBS) (10 ml of media into 90 ml PBS). We measured luciferase activity with BioLux Cypridinia
and Biolux Gaussia luciferase assay kits (New England Biolabs) on a plate reader (Biotek Synergy Neo2) with an injection protocol. All
replicates performed are biological replicates.
Fluorescent Cleavage Assay for PbuCas13b Loop Mutants
Cloning for expression and purification of PbuCas13b loop mutants was carried out by mutagenic PIPE cloning (Klock and Lesley,
2009) using PbuCas13b expression plasmid as template. Protein expression and purification was carried out as described for pre-
crRNA mutants. Detection assays were performed with 100 nM purified PbuCas13 and PbuCas13b loop mutants, 100 nM crRNA,
quenched fluorescent RNA reporter (250 nM nucleotide reporters (IDT), 0.25 mL murine RNase inhibitor (New England Biolabs),
and 100 nM of nucleic acid target in 1x CutSmart Buffer (New England Biolabs). Reactions were allowed to proceed for 3 hr at
37C on a fluorescent plate reader (BioTek) with fluorescent kinetics measured every 5 min. Cleavage activity of four technical rep-
licates is shown as mean + SEM, unless otherwise stated. For clustering of protein activity based on di-nucleotide motif preference,
the mean cleavage activity matrix was clustered using Euclidean distance in R using the heatmap.2 function and exported for graph-
ing in GraphPad Prism 7.
QUANTIFICATION AND STATISTICAL ANALYSIS
Crystallographic statistics were generated during refinementwith Phenix and can be found in Table 1. RNA editing experiments are the
average of four biological replicates, with the standard deviation shown. RNA knockdown experiments are the average of three biolog-
ical replicates, normalized to the average of three replicates of guide alone condition. Fluorescence collateral RNA-cleavage assays
were performed in technical quadruplicates. For eachmeasurement, initial fluorescencewas subtracted to adjust for background fluo-
rescence (background – subtracted fluorescence). Unless otherwise indicated,mean cleavage activities ±SEM from four replicates of
background-subtractedsignals are reported.For clusteringofprotein activity basedondi-nucleotidemotif preference, themeancleav-
age activity from four technical replicates was used to calculate a distance matrix based on Euclidean distance. This distance matrix
was used for clusteringwith the default ‘complete agglomeration’method. Distancematrix calculations and clusteringwere computed
using the heatmap.2 function (gplots) in R. The final clustered matrix was exported for graphing in GraphPad Prism 7.
DATA AND SOFTWARE AVAILABILITY
The accession number for the crystal structure and reflections for PbuCas13b reported in this paper is PDB: 6DTD.e5 Cell Reports 26, 3741–3751.e1–e5, March 26, 2019
